{
    "clinical_study": {
        "@rank": "72190", 
        "arm_group": [
            {
                "arm_group_label": "Morphine", 
                "arm_group_type": "Experimental", 
                "description": "Morphine in changing dosages (range between 10-60 mg twice a day). Opioid titration proceeds as follows:  starting at an oral dose of 10 mg twice per day, followed every 5 days by a dose increase of 10 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 120 mg per day had been reached."
            }, 
            {
                "arm_group_label": "Milnacipran", 
                "arm_group_type": "Active Comparator", 
                "description": "Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily).  SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached."
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical, psychophysical, behavioral or genetic factor will predict  the response to opioid\n      treatment in patients with chronic neuropathic pain."
        }, 
        "brief_title": "Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With Sciatica", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pharmacological Action (PA)", 
        "condition_browse": {
            "mesh_term": "Neuralgia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with moderate to severe chronic neuropathic pain or patients with\n             radiculitis between 18 and 75 years of age.\n\n          2. Candidates for chronic opioid therapy for nonmalignant pain as determined by treating\n             physician.\n\n          3. Patients treated with non-opioid analgetics, anti- inflammatory drugs or low opioid\n             dosage (< 30 mg of oral morphine-equivalents per day).\n\n          4. Ability to understand the purpose and instructions of the study and to sign an\n             informed consent.\n\n             -\n\n             Exclusion Criteria:\n\n        1.Diabetic Neuropathy 2.Pain in upper limbs 3.Receiving anti- depressants and/or\n        anticonvulsants 4.Pregnant women 5.Inability to comply with study protocol. 6.Allergy to\n        Opioids 7.A diagnosis of Raynaud's Syndrome 8.History of substance abuse\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01914042", 
            "org_study_id": "143-10 RMB"
        }, 
        "intervention": [
            {
                "arm_group_label": "Morphine", 
                "intervention_name": "Morphine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Milnacipran", 
                "intervention_name": "Milnacipran", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Morphine", 
                "Milnacipran", 
                "Norepinephrine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Opioid induced hyperalgesia", 
            "Neuropathic pain", 
            "Opioids", 
            "Sciatica", 
            "Serotonin-norepinephrine reuptake inhibitor (SNRI)"
        ], 
        "lastchanged_date": "July 30, 2013", 
        "location": {
            "contact": {
                "email": "e_eisenberg@rambam.health.gov.il", 
                "last_name": "Elon Eisenberg, MD", 
                "phone": "972 4 8542880"
            }, 
            "facility": {
                "address": {
                    "city": "Haifa", 
                    "country": "Israel", 
                    "zip": "31096"
                }, 
                "name": "Rambam Health Care Campus"
            }, 
            "investigator": {
                "last_name": "Elon Eisenberg, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prediction of Inter-individual Differences in the Response to Morphine by Psychophysical Assessment of Pain Enhancing and Inhibiting Mechanisms in Patients With Chronic Neuropathic Pain", 
        "overall_contact": {
            "email": "e_eisenberg@rambam.health.gov.il", 
            "last_name": "Elon Eisenberg, MD", 
            "phone": "972 4 8542880"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Neuropathic pain intensity (NPS)", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01914042"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rambam Health Care Campus", 
            "investigator_full_name": "Eisenberg Elon MD", 
            "investigator_title": "Director, Pain Research Unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Heat pain sensitivity will be determined by the use of VAS units (0-100). We'll measure the intensity of pain in response to application of brief experimental heat pain.", 
                "measure": "Heat pain intensity in a remote area (Opioid induced hyperalgesia)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Will be completed before and after treatment", 
                "measure": "The McGill Pain Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "At baseline and at the end of 4-week treatment period"
            }, 
            {
                "description": "A list of possible side effects from the administered drugs has been prepared and will be completed at all scheduled visits.\nIn addition, patients will record AEs on daily basis. If needed patients can call and report adverse events by phone.", 
                "measure": "Assessment of Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Ongoing throughout the entire study period, an expected average of 4 weeks."
            }
        ], 
        "source": "Rambam Health Care Campus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rambam Health Care Campus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}